Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Denschlag

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 6, 2021
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)Günter Emons, Jae-Weon Kim, Karin Weide, et al.
Langenbeck'S Archives of Surgery|July 10, 2023
Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas"Jens Jakob, Dimosthenis Andreou, Jens Bedke, et al.
Geburtshilfe Und Frauenheilkunde|December 5, 2022
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
Geburtshilfe Und Frauenheilkunde|October 29, 2019
Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
Geburtshilfe Und Frauenheilkunde|April 8, 2025
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024)Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK UterusDominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
Cancers|January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva StudyLinn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaboratorsDominik Denschlag, Florian Heitz, Jacobus Pfisterer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 6, 2021
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)Günter Emons, Jae-Weon Kim, Karin Weide, et al.
Langenbeck'S Archives of Surgery|July 10, 2023
Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline "Adult Soft Tissue Sarcomas"Jens Jakob, Dimosthenis Andreou, Jens Bedke, et al.
Geburtshilfe Und Frauenheilkunde|December 5, 2022
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
Geburtshilfe Und Frauenheilkunde|October 29, 2019
Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
Geburtshilfe Und Frauenheilkunde|April 8, 2025
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024)Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 25, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trialGiorgio Valabrega, Matthew A Powell, Sakari Hietanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK UterusDominik Denschlag, Bastian Czogalla, Florian Heitz, et al.
Cancers|January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva StudyLinn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Pageof 6